Meryl Bartlett advises companies on regulatory, litigation, and transactional matters involving the Food and Drug Administration (FDA) and other regulatory authorities with jurisdiction over healthcare and biotechnology.
Meryl counsels pharmaceutical, biotechnology, medical device, digital health, food, dietary supplement, cosmetic, and consumer product companies regarding all aspects of the FDA-regulated product life cycle, including, among others:
In the transactional space, Meryl advises investment banks, venture capital firms, private equity firms, and commercial lenders on regulatory diligence and disclosure matters in connection with mergers and acquisitions, equity offerings, financings, and other transactions in the life sciences sector.
A recognized thought leader, Meryl frequently speaks and writes on healthcare and life sciences topics. She is a member of the Food and Drug Law Journal’s editorial advisory board and previously served on the review committee for the Food and Drug Law Journal’s H. Thomas Austern Writing Competition.
Meryl was recently recognized for her professional excellence by Best Lawyers in their fourth and fifth editions of Best Lawyers: Ones to Watch in America for administrative/regulatory law.
She also maintains an active pro bono practice, currently serving as the firm’s liaison to the Legal Counsel for the Elderly and as a member of the Legal Counsel for the Elderly’s Young Lawyer’s Alliance.
Some of Meryl’s recent speaking engagements include: